First-line Lapatinib/Taxane Found to be Inferior to Trastuzumab/Taxane in Patients with HER2+ Metastatic Breast Cancer

Share this content:
First-line Lapatinib/Taxane Found to be Inferior to Trastuzumab/Taxane in Patients with HER2+
First-line Lapatinib/Taxane Found to be Inferior to Trastuzumab/Taxane in Patients with HER2+

CME

Program Description:

Taxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer, according to an interim analysis of an open-label phase 3 randomized study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Identify patients whose tumors overexpress HER2 and who have received prior therapy, including EGFR- and HER2 receptor tyrosine kinases.

  • Assess first-line treatment for patients with HER2+ metastatic breast cancer based on recently released randomized controlled trials.

Click Next to begin the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs